A randomised, double-blind, placebo controlled phase II study of ANAVEX 2-73 in patients with Rett Syndrome

Trial Profile

A randomised, double-blind, placebo controlled phase II study of ANAVEX 2-73 in patients with Rett Syndrome

Planning
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs ANAVEX 2-73 (Primary)
  • Indications Rett syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Aug 2017 According to an Anavex Life Sciences media release, ANAVEX2-73 has been granted Orphan Drug Designation by the FDA.
    • 19 Jan 2017 According to an Anavex Life Sciences media release, this study is expected to initiate in 2017.
    • 20 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top